Executive Overview Musculoskeletal decline—manifesting as joint stiffness, localized discomfort, and reduced physical flexibility—represents one of the most pervasive…
Executive Overview The rise of glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—has…